Literature DB >> 22409723

Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.

Kelin Li1, Kevin J Frankowski, Craig A Belon, Ben Neuenswander, Jean Ndjomou, Alicia M Hanson, Matthew A Shanahan, Frank J Schoenen, Brian S J Blagg, Jeffrey Aubé, David N Frick.   

Abstract

A screen for hepatitis C virus (HCV) NS3 helicase inhibitors revealed that the commercial dye thioflavine S was the most potent inhibitor of NS3-catalyzed DNA and RNA unwinding in the 827-compound National Cancer Institute Mechanistic Set. Thioflavine S and the related dye primuline were separated here into their pure components, all of which were oligomers of substituted benzothiazoles. The most potent compound (P4), a benzothiazole tetramer, inhibited unwinding >50% at 2 ± 1 μM, inhibited the subgenomic HCV replicon at 10 μM, and was not toxic at 100 μM. Because P4 also interacted with DNA, more specific analogues were synthesized from the abundant dimeric component of primuline. Some of the 32 analogues prepared retained ability to inhibit HCV helicase but did not appear to interact with DNA. The most potent of these specific helicase inhibitors (compound 17) was active against the replicon and inhibited the helicase more than 50% at 2.6 ± 1 μM.
© 2012 American Chemical Society

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22409723      PMCID: PMC3476947          DOI: 10.1021/jm300021v

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  36 in total

1.  Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.

Authors:  Anna Stankiewicz-Drogoń; Bernd Dörner; Thomas Erker; Anna M Boguszewska-Chachulska
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

2.  Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors.

Authors:  Jan Paeshuyse; Inge Vliegen; Lotte Coelmont; Pieter Leyssen; Oriana Tabarrini; Piet Herdewijn; Harald Mittendorfer; Johnny Easmon; Violetta Cecchetti; Ralf Bartenschlager; Gerhard Puerstinger; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

3.  New acridone-4-carboxylic acid derivatives as potential inhibitors of hepatitis C virus infection.

Authors:  Anna Stankiewicz-Drogon; Larisa G Palchykovska; Valentina G Kostina; Inna V Alexeeva; Anatoly D Shved; Anna M Boguszewska-Chachulska
Journal:  Bioorg Med Chem       Date:  2008-08-31       Impact factor: 3.641

4.  Discovery of potent nucleotide-mimicking competitive inhibitors of hepatitis C virus NS3 helicase.

Authors:  Sandra Gemma; Stefania Butini; Giuseppe Campiani; Margherita Brindisi; Samantha Zanoli; Maria Pia Romano; Pierangela Tripaldi; Luisa Savini; Isabella Fiorini; Giuseppe Borrelli; Ettore Novellino; Giovanni Maga
Journal:  Bioorg Med Chem Lett       Date:  2010-09-06       Impact factor: 2.823

5.  Hepatitis C virus subgenomic replicon requires an active NS3 RNA helicase.

Authors:  Angela M I Lam; David N Frick
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  Synthesis and DNA binding studies of a new asymmetric cyanine dye binding in the minor groove of [poly(dA-dT)]2.

Authors:  H Jonas Karlsson; Per Lincoln; Gunnar Westman
Journal:  Bioorg Med Chem       Date:  2003-03-20       Impact factor: 3.641

Review 7.  Understanding hepatitis C.

Authors:  John G McHutchison
Journal:  Am J Manag Care       Date:  2004-03       Impact factor: 2.229

8.  Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo.

Authors:  A A Kolykhalov; K Mihalik; S M Feinstone; C M Rice
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

Review 9.  Viral and cellular RNA helicases as antiviral targets.

Authors:  Ann D Kwong; B Govinda Rao; Kuan-Teh Jeang
Journal:  Nat Rev Drug Discov       Date:  2005-10       Impact factor: 84.694

10.  Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions.

Authors:  Adam Sharp; Simon J Crabb; Peter W M Johnson; Angela Hague; Ramsey Cutress; Paul A Townsend; A Ganesan; Graham Packham
Journal:  J Pharmacol Exp Ther       Date:  2009-08-18       Impact factor: 4.030

View more
  21 in total

1.  Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold.

Authors:  Ivan A Andreev; Dinesh Manvar; Maria Letizia Barreca; Dmitry S Belov; Amartya Basu; Noreena L Sweeney; Nina K Ratmanova; Evgeny R Lukyanenko; Giuseppe Manfroni; Violetta Cecchetti; David N Frick; Andrea Altieri; Neerja Kaushik-Basu; Alexander V Kurkin
Journal:  Eur J Med Chem       Date:  2015-04-10       Impact factor: 6.514

2.  Novel symmetrical phenylenediamines as potential anti-hepatitis C virus agents.

Authors:  Marcella Bassetto; Salvatore Ferla; Pieter Leyssen; Johan Neyts; Mark M Yerukhimovich; David N Frick; Rachel O'Donnell; Andrea Brancale
Journal:  Antivir Chem Chemother       Date:  2016-11-04

3.  Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.

Authors:  Jean Ndjomou; M Josie Corby; Noreena L Sweeney; Alicia M Hanson; Cihan Aydin; Akbar Ali; Celia A Schiffer; Kelin Li; Kevin J Frankowski; Frank J Schoenen; David N Frick
Journal:  ACS Chem Biol       Date:  2015-05-22       Impact factor: 5.100

4.  Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase.

Authors:  Noreena L Sweeney; Alicia M Hanson; Sourav Mukherjee; Jean Ndjomou; Brian J Geiss; J Jordan Steel; Kevin J Frankowski; Kelin Li; Frank J Schoenen; David N Frick
Journal:  ACS Infect Dis       Date:  2015-03-13       Impact factor: 5.084

5.  Primuline derivatives that mimic RNA to stimulate hepatitis C virus NS3 helicase-catalyzed ATP hydrolysis.

Authors:  Noreena L Sweeney; William R Shadrick; Sourav Mukherjee; Kelin Li; Kevin J Frankowski; Frank J Schoenen; David N Frick
Journal:  J Biol Chem       Date:  2013-05-23       Impact factor: 5.157

6.  Intercepting the Breslow intermediate via Claisen rearrangement: synthesis of complex tertiary alcohols without organometallic reagents.

Authors:  Sefat Alwarsh; Kolawole Ayinuola; Silvana S Dormi; Matthias C McIntosh
Journal:  Org Lett       Date:  2012-12-05       Impact factor: 6.005

7.  Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.

Authors:  Jean Ndjomou; Rajesh Kolli; Sourav Mukherjee; William R Shadrick; Alicia M Hanson; Noreena L Sweeney; Diana Bartczak; Kelin Li; Kevin J Frankowski; Frank J Schoenen; David N Frick
Journal:  Antiviral Res       Date:  2012-08-25       Impact factor: 5.970

8.  Aurintricarboxylic acid modulates the affinity of hepatitis C virus NS3 helicase for both nucleic acid and ATP.

Authors:  William R Shadrick; Sourav Mukherjee; Alicia M Hanson; Noreena L Sweeney; David N Frick
Journal:  Biochemistry       Date:  2013-08-26       Impact factor: 3.162

9.  Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays.

Authors:  Sourav Mukherjee; Alicia M Hanson; William R Shadrick; Jean Ndjomou; Noreena L Sweeney; John J Hernandez; Diana Bartczak; Kelin Li; Kevin J Frankowski; Julie A Heck; Leggy A Arnold; Frank J Schoenen; David N Frick
Journal:  Nucleic Acids Res       Date:  2012-06-27       Impact factor: 16.971

Review 10.  Discovering new medicines targeting helicases: challenges and recent progress.

Authors:  William R Shadrick; Jean Ndjomou; Rajesh Kolli; Sourav Mukherjee; Alicia M Hanson; David N Frick
Journal:  J Biomol Screen       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.